您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > ALK5-IN-34
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
ALK5-IN-34
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
ALK5-IN-34图片
CAS NO:2785430-90-0
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议

产品介绍
ALK5-IN-34 是一种选择性的激活素受体样激酶 (ALK) 抑制剂,具有口服活性。ALK5-IN-34 可以抑制激活素受体样激酶的活性,IC50值 ≤10 nM。ALK5-IN-34 还具有抑制肿瘤生长的作用,可用于癌症等增殖性疾病的研究。
生物活性

ALK5-IN-34 is an selective orally activeactivin receptor-like kinase (ALK)inhibitor. ALK5-IN-34 can inhibit the activity of ALK5-IN-34 with anIC50value of ≤10 nM. ALK5-IN-34 also has inhibitory of tumor growth and can be used for the research of proliferative diseases, such ascancer[1].

IC50& Target[1]

ALK5

<10 nM (IC50)

体外研究
(In Vitro)

ALK5-IN-34 (EX-11) has kinase inhibition of ALK5 with an IC50value of ≤10 nM[1].
ALK5-IN-34 has kinase selectivity of ALK2/ALK5 with an IC50value of <100 nM[1].
ALK5-IN-34 shows TGFB-RI inhibition (RD-SMAD receptor activity) with an IC50value of ≤100 nM[1].
ALK5-IN-34 (1 μM-10 nM) inhibits the expression of TGF-β-mediated alpha-SMA in a full concentration-dependent[1].
ALK5-IN-34 (30, 300 and 3000 nM) suppresses the Treg frequency in a dose dependent manner[1].
ALK5-IN-34 (0-0.1 μM; for 6 days or 7 days) inhibits FOXL2CI34W-driven growth in KGN and COV434 cells with IC50 values of 140 nM and﹥10 μM, respectively[1].
ALK5-IN-34 (10, 100 and 1000 nM; 2 h) shows a dose-dependent decrease in pSmad2 in KGN cell line[1].
ALK5-IN-34 (30, 300 nM; 24 h) reverses the upregulation of gene expression in dose dependentent[1].
ALK5-IN-34 (30, 300 nM; 24 h) increases HLA class I expression in dose-dependent[1].

Cell Viability Assay[1]

Cell Line:KGN and COV434 cell lines
Concentration:0-0.1 μM
Incubation Time:for 6 days or 7 days
Result:Inhibited FOXL2CI34W-driven growth.

RT-PCR[1]

Cell Line:Human primary dermal fibroblasts
Concentration:30, 300 nM
Incubation Time:24 h
Result:Reversed the upregulation of gene expression with TGFB stimulation.
体内研究
(In Vivo)

ALK5-IN-34 (EX-11) (oral; 10-100 mg/kg) reduces the phopho SMAD2 levels (p-SMAD2) in a dose dependent manner in A549 murine xenograft model[1].
ALK5-IN-34 (oral; 75 mg/kg; 0-24 h) shows reversely correlated between PK and tumor PD (pSMAD2 levels)[1].
ALK5-IN-34 (oral; 150 mg/kg; bid; for 22 days) increases overall survival in ES-2 ovarian cancer mouse xenograft model and can delay progression[1].
ALK5-IN-34 (p.o.; 75, 150 mg/kg; twice a day; for 21days) shows tumor growth inhibition (TGI) and increases the survival when combining with anti-PD-L1/anti-PD-1 in Syngeneic TNBC Model and in Subcutaneous Cloudman S91 melanoma model[1].
ALK5-IN-34 (oral; 300, 1000 mg/kg; bid for 5 days) has good tolerability and safety margin in Tolerability Model[1].

Animal Model:A549 murine xenograft model[1]
Dosage:10, 50, 75 and 100 mg/kg
Administration:oral gavage
Result:Exhibited 92.5% inhibition based upon the average p-SMAD2 levels (75 mg/kg).
Animal Model:EMT6 Syngeneic TNBC Model[1]
Dosage:75, 150 mg/kg
Administration:p.o., twice a day, for 21days
Result:Resulted significantly tumor growth inhibition (TGI) by 37% at 150 mg/kg.
Result in significant tumor growth inhibition (TGI) with combination of anti-PD-LI and resulted in a significant increase in mean survival by 37%.
Resulted in significant TGI by 34% with combination of anti-PD-1 and resulted in significant increase in mean survival by 26%.
Decreased the intra-tumoral pressure.
Animal Model:Cachexia Model[1]
Dosage:150 mg/kg
Administration:oral gavage, twice a day for 22 days
Result:Showed reduction in total fluid volume and high whole limb weights.
分子量

413.48

Formula

C23H23N7O

CAS 号

2785430-90-0

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.